$233.15
+0.94
(+0.4%)▲
Insights on Becton, Dickinson And Company
Revenue is down for the last 2 quarters, 5.08B → 4.70B (in $), with an average decrease of 7.5% per quarter
Netprofit is up for the last 2 quarters, 108.0M → 281.0M (in $), with an average increase of 61.6% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 39.0% return, outperforming this stock by 47.4%
In the last 3 years, Intuitive Surgical, Inc. has given 38.1% return, outperforming this stock by 49.1%
1.15%
Downside
Day's Volatility :1.15%
Upside
0.0%
2.21%
Downside
52 Weeks Volatility :19.72%
Upside
17.91%
Period | Becton, Dickinson And Company | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -1.19% | -0.7% | 5.0% |
6 Months | -10.48% | 6.6% | 16.4% |
1 Year | -8.43% | 3.7% | 20.9% |
3 Years | -10.33% | 14.0% | 20.0% |
Market Capitalization | 67.8B |
Book Value | $87.68 |
Dividend Share | 3.68 |
Dividend Yield | 1.64% |
Earnings Per Share (EPS) | 4.37 |
PE Ratio | 52.86 |
PEG Ratio | 1.34 |
Wall Street Target Price | 278.54 |
Profit Margin | 6.44% |
Operating Margin TTM | 10.69% |
Return On Assets TTM | 3.12% |
Return On Equity TTM | 5.13% |
Revenue TTM | 19.5B |
Revenue Per Share TTM | 67.72 |
Quarterly Revenue Growth YOY | 2.6% |
Gross Profit TTM | 8.8B |
EBITDA | 4.9B |
Diluted Eps TTM | 4.37 |
Quarterly Earnings Growth YOY | -0.43 |
EPS Estimate Current Year | 12.95 |
EPS Estimate Next Year | 14.35 |
EPS Estimate Current Quarter | 2.4 |
EPS Estimate Next Quarter | 2.99 |
What analysts predicted
Upside of 19.47%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 16.0B | ↑ 32.17% |
Net Income | 311.0M | ↓ 71.73% |
Net Profit Margin | 1.95% | ↓ 7.15% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 17.3B | ↑ 8.18% |
Net Income | 1.2B | ↑ 292.28% |
Net Profit Margin | 7.06% | ↑ 5.11% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 17.1B | ↓ 1.0% |
Net Income | 874.0M | ↓ 28.36% |
Net Profit Margin | 5.11% | ↓ 1.95% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 20.2B | ↑ 18.29% |
Net Income | 2.1B | ↑ 139.36% |
Net Profit Margin | 10.33% | ↑ 5.22% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 18.9B | ↓ 6.81% |
Net Income | 1.8B | ↓ 14.96% |
Net Profit Margin | 9.43% | ↓ 0.9% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 19.4B | ↑ 2.66% |
Net Income | 1.5B | ↓ 16.58% |
Net Profit Margin | 7.66% | ↓ 1.77% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↑ 2.59% |
Net Income | 287.0M | ↓ 20.28% |
Net Profit Margin | 6.03% | ↓ 1.73% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 4.6B | ↓ 3.68% |
Net Income | 509.0M | ↑ 77.35% |
Net Profit Margin | 11.1% | ↑ 5.07% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↑ 5.12% |
Net Income | 460.0M | ↓ 9.63% |
Net Profit Margin | 9.54% | ↓ 1.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.9B | ↑ 1.18% |
Net Income | 407.0M | ↓ 11.52% |
Net Profit Margin | 8.34% | ↓ 1.2% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.1B | ↑ 4.28% |
Net Income | 108.0M | ↓ 73.46% |
Net Profit Margin | 2.12% | ↓ 6.22% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.7B | ↓ 7.49% |
Net Income | 281.0M | ↑ 160.19% |
Net Profit Margin | 5.97% | ↑ 3.85% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 53.9B | ↑ 42.85% |
Total Liabilities | 32.9B | ↑ 32.78% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 51.8B | ↓ 3.83% |
Total Liabilities | 30.7B | ↓ 6.82% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 54.0B | ↑ 4.19% |
Total Liabilities | 30.2B | ↓ 1.4% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 53.9B | ↓ 0.27% |
Total Liabilities | 30.2B | ↓ 0.16% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 52.9B | ↓ 1.73% |
Total Liabilities | 27.6B | ↓ 8.47% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 52.8B | ↓ 0.29% |
Total Liabilities | 27.0B | ↓ 2.35% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 52.9B | ↓ 0.5% |
Total Liabilities | 27.6B | ↓ 0.26% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 53.1B | ↑ 0.37% |
Total Liabilities | 27.6B | ↓ 0.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 54.4B | ↑ 2.38% |
Total Liabilities | 28.7B | ↑ 3.9% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 53.0B | ↓ 2.53% |
Total Liabilities | 27.1B | ↓ 5.66% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 52.8B | ↓ 0.45% |
Total Liabilities | 27.0B | ↓ 0.35% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 52.3B | ↓ 0.96% |
Total Liabilities | 26.9B | ↓ 0.16% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.9B | ↑ 12.35% |
Investing Cash Flow | -15.8B | ↑ 1692.64% |
Financing Cash Flow | -57.0M | ↓ 100.52% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.3B | ↑ 16.23% |
Investing Cash Flow | -741.0M | ↓ 95.32% |
Financing Cash Flow | -3.2B | ↑ 5556.14% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.5B | ↑ 6.28% |
Investing Cash Flow | -1.2B | ↑ 66.26% |
Financing Cash Flow | 22.0M | ↓ 100.68% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.6B | ↑ 31.31% |
Investing Cash Flow | -1.9B | ↑ 52.6% |
Financing Cash Flow | -3.3B | ↓ 15127.27% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.6B | ↓ 43.34% |
Investing Cash Flow | -3.2B | ↑ 71.28% |
Financing Cash Flow | -591.0M | ↓ 82.12% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.0B | ↑ 13.52% |
Investing Cash Flow | -716.0M | ↓ 77.76% |
Financing Cash Flow | -2.0B | ↑ 231.13% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 971.0M | ↑ 78.49% |
Investing Cash Flow | -2.0B | ↑ 786.22% |
Financing Cash Flow | -550.0M | ↓ 34.99% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 400.0M | ↓ 58.81% |
Investing Cash Flow | -291.0M | ↓ 85.41% |
Financing Cash Flow | -533.0M | ↓ 3.09% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 184.0M | ↓ 54.0% |
Investing Cash Flow | -233.0M | ↓ 19.93% |
Financing Cash Flow | 1.4B | ↓ 356.47% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↑ 486.96% |
Investing Cash Flow | -329.0M | ↑ 41.2% |
Financing Cash Flow | -1.8B | ↓ 231.16% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.3B | ↑ 22.69% |
Investing Cash Flow | -716.0M | ↑ 117.63% |
Financing Cash Flow | -998.0M | ↓ 44.34% |
Sell
Neutral
Buy
Becton, Dickinson And Company is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Becton, Dickinson And Company | -2.32% | -10.48% | -8.43% | -10.33% | 1.9% |
Intuitive Surgical, Inc. | -4.7% | 35.81% | 38.95% | 38.38% | 112.57% |
Resmed Inc. | -8.97% | 22.05% | -22.01% | -15.48% | 75.2% |
West Pharmaceutical Services Inc | -4.64% | 0.62% | 4.23% | 19.12% | 238.38% |
Alcon Ag | -6.1% | 7.94% | 11.1% | 7.08% | 42.78% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Becton, Dickinson And Company | 52.86 | 52.86 | 1.34 | 12.95 | 0.05 | 0.03 | 0.02 | 87.68 |
Intuitive Surgical, Inc. | 75.26 | 75.26 | 7.13 | 6.25 | 0.15 | 0.08 | NA | 37.77 |
Resmed Inc. | 30.61 | 30.61 | 1.75 | 7.41 | 0.22 | 0.11 | 0.01 | 30.47 |
West Pharmaceutical Services Inc | 48.1 | 48.1 | 6.72 | 7.62 | 0.21 | 0.12 | 0.0 | 39.2 |
Alcon Ag | 40.62 | 40.62 | 4.59 | 3.06 | 0.05 | 0.02 | 0.0 | 41.81 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Becton, Dickinson And Company | Buy | $67.8B | 1.9% | 52.86 | 6.44% |
Intuitive Surgical, Inc. | Buy | $134.2B | 112.57% | 75.26 | 25.24% |
Resmed Inc. | Buy | $27.2B | 75.2% | 30.61 | 19.77% |
West Pharmaceutical Services Inc | Buy | $27.8B | 238.38% | 48.1 | 20.12% |
Alcon Ag | Buy | $39.5B | 42.78% | 40.62 | 10.3% |
Vanguard Group Inc
BlackRock Inc
State Street Corporation
Morgan Stanley - Brokerage Accounts
T. Rowe Price Associates, Inc.
T. Rowe Price Investment Management,Inc.
In the quarter ending March,2024. Becton, Dickinson And Company has declared dividend of $0.95
Read MoreBecton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.
Organization | Becton, Dickinson And Company |
Employees | 73000 |
CEO | Mr. Thomas E. Polen Jr. |
Industry | Health Technology |
Targa Resources Corp.
$233.15
+0.4%
Sirius Xm Holdings Inc.
$233.15
+0.4%
Mbs Ishares
$233.15
+0.4%
Aspen Technology Inc
$233.15
+0.4%
Microstrategy Inc.
$233.15
+0.4%
Lowe's Companies Inc.
$233.15
+0.4%
Avantor Inc
$233.15
+0.4%
Cognizant Technology Solutions Corp.
$233.15
+0.4%
Consumer Staples Select Sector Spdr
$233.15
+0.4%